GCG and metabolic syndrome: Both possibilities raise the question of whether therapy with GLP-1 agonists, currently in widespread clinical use for metabolic syndrome and type 2 diabetes, may be beneficial by modulating inflammation and pyroptosis in ART-treated PWH with signatures of IA.